• Submit to JPM Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• For Librarians
• About
• Open Access Policy

• Abstract
• Full-Text HTML
• Full-Text PDF [911 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Lee, JJ. A.
• Yokota, T
• [+] on Google Scholar
• Lee, JJ. A.
• Yokota, T
• [+] on PubMed
• Lee, JJ. A.
• Yokota, T

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter
• More services

Open AccessThis article is

• freely available
• re-usable

J. Pers. Med. 2013, 3(3), 144-176; doi:10.3390/jpm3030144

Review

Antisense Therapy in Neurology

Joshua J. A. Lee ¹ and Toshifumi Yokota ^1,2,*

¹ Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, 8812-112 St, Edmonton T6G 2H7, Canada ² The Friends of Garrett Cumming Research and Muscular Dystrophy Canada HM Toupin Neurological Science Research Chair, 8812-112 St, Edmonton T6G 2H7, Canada

* Author to whom correspondence should be addressed.

Received: 27 May 2013; in revised form: 26 July 2013 / Accepted: 29 July 2013 / Published: 2 August 2013

Download PDF Full-Text [911 KB, Updated Version, uploaded 12 August 2013 12:01 CEST]

The original version is still available [548 KB, uploaded 2 August 2013 11:49 CEST]

Abstract: Antisense therapy is an approach to fighting diseases using short DNA-like molecules called antisense oligonucleotides. Recently, antisense therapy has emerged as an exciting and promising strategy for the treatment of various neurodegenerative and neuromuscular disorders. Previous and ongoing pre-clinical and clinical trials have provided encouraging early results. Spinal muscular atrophy (SMA), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy (DMD), Fukuyama congenital muscular dystrophy (FCMD), dysferlinopathy (including limb-girdle muscular dystrophy 2B; LGMD2B, Miyoshi myopathy; MM, and distal myopathy with anterior tibial onset; DMAT), and myotonic dystrophy (DM) are all reported to be promising targets for antisense therapy. This paper focuses on the current progress of antisense therapies in neurology.

Keywords: Duchenne muscular dystrophy (DMD); Fukuyama congenital muscular dystrophy (FCMD); myotonic dystrophy (DM); spinal muscular atrophy (SMA); Huntington’s disease (HD); amyotrophic lateral sclerosis (ALS); limb-girdle muscular dystrophy 2B (LGMD2B); Miyoshi myopathy (MM); distal myopathy with anterior tibial onset (DMAT); antisense therapy

Article Statistics

Citations to this Article

Cite This Article